Full-Time

District Leader

Southwest

Posted on 9/18/2025

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$142.5k - $199.5k/yr

+ Incentive + Stock Equity

Phoenix, AZ, USA + 1 more

More locations: San Diego, CA, USA

In Person

Field-based role; travel 50%+ within AZ/NV/Southern CA; no remote work.

Category
Sales & Account Management (1)
Required Skills
Sales
Marketing
Data Analysis
Requirements
  • Live in geography AZ, NV, Southern California.
  • Travel 50%+ within the selling geography and to district meetings, other conventions, and headquarters.
  • Bachelor’s degree in business, science, or related field.
  • A Master’s degree (MBA or advanced science/medical degree) is strongly preferred.
  • 8+ years of relevant experience in healthcare or pharmaceutical.
  • Proven track record of launch experience strongly preferred.
  • 2+ years Eye Care experience strongly preferred.
  • Previous frontline leadership experience strongly preferred.
  • Demonstrated strategic leadership, experience translating brand strategy into district goals, objectives and execution; adjusting plans and tactics to meet changing market dynamics; utilizing data to guide priorities, coaching, activity, and behavior.
  • Effective talent management, coaching, persuasion, mentoring & communication skills.
  • Established track record with evidence of excellent problem solving, collaboration, leadership & communication skills.
  • Collaboration experience working with Marketing, Commercial Operations, Market Access, Training & Development, Medical Affairs, & other cross-functional teams.
  • Highly adaptable to change, able to pivot, respond & lead given new market information in a fast-paced environment.
  • Strong communication and change management skills required, in addition to ability to build strong relationships both vertically & horizontally.
  • Proven ability to escalate difficult issues & make tough decisions.
  • Leadership & Management
  • Building Teams & Culture
  • Impact & Influence
  • Customer Orientation
  • Decision Making/Judgment
  • Aligning Teams for Performance / Change Leadership
  • Teamwork & Collaboration
Responsibilities
  • Attract, hire, inspire, develop, & retain a diverse team of high performing frontline sales representatives focused on elite customer engagement.
  • Drive our values of commitment, empowerment and teamwork which includes extreme ownership, high accountability, continuous improvement & relentless pursuit of excellence through trust, coaching, development, recognition, & rewards.
  • Champion compliant promotion and align execution across frontline sales representatives.
  • Drive the launch & ongoing performance by inspiring outstanding district and territory results with weekly, monthly, quarterly, & annual accountability & recognition measures.
  • Work with trainers & marketing to set priorities for critical development points & drive effective sales meetings.
  • Partner with Sales Directors, VP of Sales, HR & Training to ensure ongoing skill building across frontline leadership teams.
  • Establish a clear customer focus by developing 1:1 relationships with important district customers.
  • Collaborate directly with customers & build strong relationships with key accounts in the geography to advance the selling process & gather important feedback.
  • Drive key customer engagement while attending select district & national level customer conventions.
  • Connect the broader organization to important & influential district customers.
  • Set clear expectations and performance goals across the geography & implement systems of accountability to ensure consistent top tier execution.
  • Ensure actionable business plans are set - align all selling activities to drive impact.
  • Analyze sales results to provide coaching, guidance & selling direction to team members.
  • Achieve success and be prepared to adapt in a complex selling environment partnering with all key stakeholders: marketing, market access, medical affairs, sales ops, inside sales, training, & others.
  • Conduct field rides with sales professionals – coach to execution excellence.
  • Provide frontline feedback & insights to sales leadership, marketing, market access, sales ops & other stakeholders to hone sales strategies.
  • Ensure district expenses are aligned to budgets & set to maximize impact.
  • Ensure compliance across the team & adhere to all company & industry compliance guidelines.
Desired Qualifications
  • MBA or advanced science/medical degree strongly preferred.
  • Eye Care experience strongly preferred.
  • Previous frontline leadership experience strongly preferred.
  • Proven track record of launch experience strongly preferred.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tarsus Pharamceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

5%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

INACTIVE